Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31349496 | 0.88 | HCAR1 (0.39) | HCAR1TGFBR1GPR119EPHX2AR | |
| SCHEMBL31349483 | 0.84 | EPHX2 (0.38) | HCAR1TGFBR1GPR119EPHX2STS | |
| SCHEMBL31349447 | 0.81 | USP30 (0.42) | HCAR1USP30TGFBR1GPR119EPHX2 | |
| SCHEMBL20444529 | 0.79 | USP30 (0.45) | HCAR1USP30TGFBR1FPR2RORC | |
| SCHEMBL31349589 | 0.78 | MAP3K12 (0.36) | HCAR1IDO1 | |
| SCHEMBL15819673 | 0.76 | HCAR1 (0.45) | HCAR1USP30TGFBR1GPR119FPR2 | |
| SCHEMBL25319241 | 0.74 | AR (0.39) | HCAR1AR | |
| SCHEMBL30507492 | 0.74 | AR (0.39) | HCAR1AR | |
| SCHEMBL26023700 | 0.74 | AR (0.39) | HCAR1AR | |
| SCHEMBL31698362 | 0.74 | ABL1 (0.37) | HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |